Publication:
Cancer-specific mortality in T1a renal cell carcinoma treated with local tumor destruction versus partial nephrectomy

dc.contributor.coauthorSorce, Gabriele
dc.contributor.coauthorHoeh, Benedikt
dc.contributor.coauthorHohenhorst, Lukas
dc.contributor.coauthorPanunzio, Andrea
dc.contributor.coauthorTappero, Stefano
dc.contributor.coauthorTian, Zhe
dc.contributor.coauthorKokorovic, Andrea
dc.contributor.coauthorLarcher, Alessandro
dc.contributor.coauthorCapitanio, Umberto
dc.contributor.coauthorTerrone, Carlo
dc.contributor.coauthorChun, Felix K.H.
dc.contributor.coauthorAntonelli, Alessandro
dc.contributor.coauthorSaad, Fred
dc.contributor.coauthorShariat, Shahrokh F.
dc.contributor.coauthorMontorsi, Francesco
dc.contributor.coauthorBriganti, Alberto
dc.contributor.coauthorKarakiewicz, Pierre I.
dc.contributor.kuauthorTilki, Derya
dc.contributor.kuprofileOther
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokidN/A
dc.date.accessioned2024-11-09T23:43:38Z
dc.date.issued2023
dc.description.abstractBackground: Large-scale analyses addressing cancer-specific mortality (CSM) in T1a renal cell carcinoma (RCC) patients treated with local tumor destruction (LTD), relative to partial nephrectomy (PN), are scarce. Objective: To compare CSM after LTD versus PN. Design, setting, and participants: Within the Surveillance, Epidemiology, and End Results (SEER) database (2004–2018), we identified patients with clinical T1a stage RCC treated with LTD or PN. Outcome measurements and statistical analyses: After 1:1 ratio propensity score matching (PSM) between patients treated with LTD versus PN, competing risks regression (CRR) models addressed CSM, after adjustment for other-cause mortality (OCM) and other covariates (age, tumor size, tumor grade, and histological subtype). Results and limitations: Relative to the 35 984 PN patients, 5936 LTD patients were older and more frequently harbored unknown RCC histological subtype or unknown grade. After 1:1 PSM that resulted in 5352 LTD versus 5352 PN patients, the 10-yr CSM rate was 8.7% versus 5.5%. In multivariable CRR models, LTD was associated with higher CSM, relative to PN (hazard ratio [HR]: 1.58, p < 0.001). Subgroup analyses revealed invariably higher CSM after LTD versus PN in patients with tumor size ≤3 cm (10-yr CSM 7.2% vs 5.3%, multivariable HR: 1.47, p < 0.001) and in patients with tumor size 3.1–4 cm (10-yr CSM 11.4% vs 6.1%, multivariable HR: 1.72, p < 0.001). Lack of information regarding earlier cancer controls, retreatment, tumor location within the kidney, and type of surgery represented limitations. Conclusions: In T1a RCC patients, LTD is invariably associated with higher CSM relative to PN, even after adjustment for OCM and all available patient and tumor characteristics, and regardless of tumor size considerations. However, the magnitude of CSM disadvantage was more pronounced in LTD patients with tumor size 3.1–4 cm than in those with tumor size ≤3 cm. Patient summary: In patients with small renal masses, we observed higher cancer-specific death rates for local tumor destruction (LTD) than for partial nephrectomy. The LTD disadvantage was more pronounced for patients with tumor size 3.1–4 cm, but was also present in those with tumor size ≤3 cm.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue1
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.volume9
dc.identifier.doi10.1016/j.euf.2022.07.005
dc.identifier.issn2405-4569
dc.identifier.linkhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85135196682&doi=10.1016%2fj.euf.2022.07.005&partnerID=40&md5=0c538fd0b66cc81f119b5724d823c72a
dc.identifier.scopus2-s2.0-85135196682
dc.identifier.urihttps://dx.doi.org/10.1016/j.euf.2022.07.005
dc.identifier.urihttps://hdl.handle.net/20.500.14288/13529
dc.identifier.wos991283300001
dc.keywordsCryoablation
dc.keywordsFocal therapy
dc.keywordsMicrowave ablation
dc.keywordsMinimally invasive
dc.keywordsRadiofrequency ablation Carcinoma, Renal Cell
dc.keywordsHumans
dc.keywordsKidney
dc.keywordsKidney Neoplasms
dc.keywordsNephrectomy
dc.keywordsProportional Hazards Models
dc.keywordsAdult
dc.keywordsAge distribution
dc.keywordsArticle
dc.keywordsCancer control
dc.keywordsCancer grading
dc.keywordsCancer incidence
dc.keywordsCancer mortality
dc.keywordsCancer registry
dc.keywordsCancer staging
dc.keywordsCancer therapy
dc.keywordsControlled study
dc.keywordsDescriptive research
dc.keywordsHistopathology
dc.keywordsHuman
dc.keywordsIntermethod comparison
dc.keywordsLocal tumor destruction
dc.keywordsMajor clinical study
dc.keywordsMortality rate
dc.keywordsPartial nephrectomy
dc.keywordsPropensity score
dc.keywordsRenal cell carcinoma
dc.keywordsSex difference
dc.keywordsTumor localization
dc.keywordsTumor volume
dc.keywordsKidney
dc.keywordsKidney tumor
dc.keywordsNephrectomy
dc.keywordsPathology
dc.keywordsProcedures
dc.keywordsProportional hazards model
dc.keywordsRenal cell carcinoma
dc.keywordsSurgery
dc.languageEnglish
dc.publisherElsevier
dc.sourceEuropean Urology Focus
dc.subjectUrology
dc.subjectNephrology
dc.titleCancer-specific mortality in T1a renal cell carcinoma treated with local tumor destruction versus partial nephrectomy
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0001-7033-1380
local.contributor.kuauthorTilki, Derya

Files